HCAT vs. STTK, OSUR, VRCA, KRRO, NGNE, REPL, CCCC, ESPR, MREO, and TERN
Should you be buying Health Catalyst stock or one of its competitors? The main competitors of Health Catalyst include Shattuck Labs (STTK), OraSure Technologies (OSUR), Verrica Pharmaceuticals (VRCA), Korro Bio (KRRO), Neurogene (NGNE), Replimune Group (REPL), C4 Therapeutics (CCCC), Esperion Therapeutics (ESPR), Mereo BioPharma Group (MREO), and Terns Pharmaceuticals (TERN). These companies are all part of the "medical" sector.
Shattuck Labs (NASDAQ:STTK) and Health Catalyst (NASDAQ:HCAT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability.
In the previous week, Shattuck Labs had 6 more articles in the media than Health Catalyst. MarketBeat recorded 11 mentions for Shattuck Labs and 5 mentions for Health Catalyst. Shattuck Labs' average media sentiment score of 0.55 beat Health Catalyst's score of 0.36 indicating that Health Catalyst is being referred to more favorably in the news media.
Health Catalyst received 117 more outperform votes than Shattuck Labs when rated by MarketBeat users. However, 76.32% of users gave Shattuck Labs an outperform vote while only 67.59% of users gave Health Catalyst an outperform vote.
Shattuck Labs has higher earnings, but lower revenue than Health Catalyst. Shattuck Labs is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.
Shattuck Labs has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Health Catalyst has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 85.0% of Health Catalyst shares are owned by institutional investors. 10.5% of Shattuck Labs shares are owned by company insiders. Comparatively, 2.7% of Health Catalyst shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Health Catalyst has a net margin of -35.56% compared to Health Catalyst's net margin of -3,133.63%. Shattuck Labs' return on equity of -11.86% beat Health Catalyst's return on equity.
Shattuck Labs currently has a consensus target price of $20.00, suggesting a potential upside of 168.46%. Health Catalyst has a consensus target price of $12.18, suggesting a potential upside of 76.17%. Given Health Catalyst's stronger consensus rating and higher probable upside, research analysts clearly believe Shattuck Labs is more favorable than Health Catalyst.
Summary
Health Catalyst beats Shattuck Labs on 10 of the 18 factors compared between the two stocks.
Get Health Catalyst News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Catalyst Competitors List
Related Companies and Tools
